The safety and tolerability of epacadostat alone and in combination with pembrolizumab in patients with advanced solid tumors: results from a first-in-Japanese phase I study (KEYNOTE-434)

被引：0
|
作者：
Toshihiko Doi
Yutaka Fujiwara
Kohei Shitara
Toshio Shimizu
Kan Yonemori
Nobuaki Matsubara
Izumi Ohno
Takahiro Kogawa
Yoichi Naito
Lance Leopold
Mihaela Munteanu
Naoyoshi Yatsuzuka
Shi Rong Han
Ayman Samkari
Noboru Yamamoto
机构：
[1] National Cancer Center Hospital East,Department of Experimental Therapeutics
[2] National Cancer Center Hospital,Department of Experimental Therapeutics
[3] Mitsui Memorial Hospital,Department of Respiratory Medicine
[4] Incyte Corporation,Department of Clinical Oncology
[5] Clinical Development,undefined
[6] MSD K.K. Oncology Science Unit,undefined
[7] Merck & Co.,undefined
[8] Inc.,undefined
来源：
Investigational New Drugs | 2021年 / 39卷
关键词：
Advanced solid tumors; Epacadostat (INCB024360); Japanese; Pembrolizumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：152 / 162
页数：10
相关论文
共 50 条
  • [31] Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study
    Strosberg, Jonathan
    Mizuno, Nobumasa
    Doi, Toshihiko
    Grande, Enrique
    Delord, Jean-Pierre
    Shapira-Frommer, Ronnie
    Bergsland, Emily
    Shah, Manisha
    Fakih, Marwan
    Takahashi, Shunji
    Piha-Paul, Sarina A.
    O'Neil, Bert
    Thomas, Sajeve
    Lolkema, Martijn P.
    Chen, Menghui
    Ibrahim, Nageatte
    Norwood, Kevin
    Hadoux, Julien
    CLINICAL CANCER RESEARCH, 2020, 26 (09) : 2124 - 2130
  • [32] Epacadostat plus pembrolizumab in patients with advanced urothelial carcinoma: Preliminary phase I/II results of ECHO-202/KEYNOTE-037.
    Smith, David C.
    Gajewski, Thomas
    Mid, Omid Ha
    Wasser, Jeffrey S.
    Olszanski, Anthony J.
    Patel, Sandip P.
    Mamtani, Ronac
    Schmidt, Emmett V.
    Zhao, Yufan
    Maleski, Janet E.
    Gangadhar, Tara C.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [33] Phase I dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumors
    Seto, Takashi
    Esaki, Taito
    Hirai, Fumihiko
    Arita, Shuji
    Nosaki, Kaname
    Makiyama, Akitaka
    Kometani, Takuro
    Fujimoto, Chinatsu
    Hamatake, Motoharu
    Takeoka, Hiroaki
    Agbo, Felix
    Shi, Xiaojin
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [34] Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study
    Cascone, T.
    Sacks, R. L.
    Subbiah, I. M.
    Drobnitzky, N.
    Piha-Paul, S. A.
    Hong, D. S.
    Hess, K. R.
    Amini, B.
    Bhatt, T.
    Fu, S.
    Naing, A.
    Janku, F.
    Karp, D.
    Falchook, G. S.
    Conley, A. P.
    Sherman, S., I
    Meric-Bernstam, F.
    Ryan, A. J.
    Heymach, J., V
    Subbiah, V
    ESMO OPEN, 2021, 6 (02)
  • [35] Phase I study of olaratumab in Japanese patients with advanced solid tumors
    Doi, Toshihiko
    Ma, Yan
    Dontabhaktuni, Aruna
    Nippgen, Cornelia
    Nippgen, Johannes
    Ohtsu, Atsushi
    CANCER SCIENCE, 2014, 105 (07) : 862 - 869
  • [36] A phase I study of resminostat in Japanese patients with advanced solid tumors
    Satoru Kitazono
    Yutaka Fujiwara
    Shinji Nakamichi
    Hidenori Mizugaki
    Hiroshi Nokihara
    Noboru Yamamoto
    Yasuhide Yamada
    Eri Inukai
    Osamu Nakamura
    Tomohide Tamura
    Cancer Chemotherapy and Pharmacology, 2015, 75 : 1155 - 1161
  • [37] A phase I study of resminostat in Japanese patients with advanced solid tumors
    Kitazono, Satoru
    Fujiwara, Yutaka
    Nakamichi, Shinji
    Mizugaki, Hidenori
    Nokihara, Hiroshi
    Yamamoto, Noboru
    Yamada, Yasuhide
    Inukai, Eri
    Nakamura, Osamu
    Tamura, Tomohide
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (06) : 1155 - 1161
  • [38] Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
    Bang, Yung-Jue
    Kang, Yoon-Koo
    Catenacci, Daniel V.
    Muro, Kei
    Fuchs, Charles S.
    Geva, Ravit
    Hara, Hiroki
    Golan, Talia
    Garrido, Marcelo
    Jalal, Shadia I.
    Borg, Christophe
    Doi, Toshihiko
    Yoon, Harry H.
    Savage, Mary J.
    Wang, Jiangdian
    Dalal, Rita P.
    Shah, Sukrut
    Wainberg, Zev A.
    Chung, Hyun Cheol
    GASTRIC CANCER, 2019, 22 (04) : 828 - 837
  • [39] Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
    Yung-Jue Bang
    Yoon-Koo Kang
    Daniel V. Catenacci
    Kei Muro
    Charles S. Fuchs
    Ravit Geva
    Hiroki Hara
    Talia Golan
    Marcelo Garrido
    Shadia I. Jalal
    Christophe Borg
    Toshihiko Doi
    Harry H. Yoon
    Mary J. Savage
    Jiangdian Wang
    Rita P. Dalal
    Sukrut Shah
    Zev A. Wainberg
    Hyun Cheol Chung
    Gastric Cancer, 2019, 22 : 828 - 837
  • [40] Phase I study of BI 836880 alone or combined with ezabenlimab in Japanese patients (pts) with advanced solid tumors
    Yamazaki, Kentaro
    Koyama, Takafumi
    Shimizu, Toshio
    Todaka, Akiko
    Kawakami, Takeshi
    Yoon, Jangsoo
    Erzen, Damijan
    Hou, Jianrui
    Yamamoto, Noboru
    ANNALS OF ONCOLOGY, 2022, 33 : S506 - S506
12345